Department of Internal Medicine, University of Nebraska College of Medicine, 985520 Nebraska Medical Center, Omaha, NE, 68198, USA.
Penn State College of Medicine, 700 HMC Crescent Road, Hershey, PA, 17033, USA.
BMC Infect Dis. 2021 Jan 13;21(1):68. doi: 10.1186/s12879-020-05723-y.
BACKGROUND: Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus that was first discovered in December 2019 in Wuhan, China. With the growing numbers of community spread cases worldwide, the World Health Organization (WHO) declared the COVID-19 outbreak as a pandemic on March 11, 2020. Like influenza viruses, SARS-CoV-2 is thought to be mainly transmitted by droplets and direct contact, and COVID-19 has a similar disease presentation to influenza. Here we present a case of influenza A and COVID-19 co-infection in a 60-year-old man with end-stage renal disease (ESRD) on hemodialysis. CASE PRESENTATION: A 60-year-old man with ESRD on hemodialysis presented for worsening cough, shortness of breath, and diarrhea. The patient first developed a mild fever (37.8 °C) during hemodialysis 3 days prior to presentation and has been experiencing worsening flu-like symptoms, including fever of up to 38.6 °C, non-productive cough, generalized abdominal pain, nausea, vomiting, and liquid green diarrhea. He lives alone at home with no known sick contacts and denies any recent travel or visits to healthcare facilities other than the local dialysis center. Rapid flu test was positive for influenza A. Procalcitonin was elevated at 5.21 ng/mL with a normal white blood cell (WBC) count. Computed tomography (CT) chest demonstrated multifocal areas of consolidation and extensive mediastinal and hilar adenopathy concerning for pneumonia. He was admitted to the biocontainment unit of Nebraska Medicine for concerns of possible COVID-19 and was started on oseltamivir for influenza and vancomycin/cefepime for the probable bacterial cause of his pneumonia and diarrhea. Gastrointestinal (GI) pathogen panel and Clostridioides difficile toxin assay were negative. On the second day of admission, initial nasopharyngeal swab came back positive for SARS-CoV-2 by real-time reverse-transcriptase polymerase chain reaction (RT-PCR). The patient received supportive care and resumed bedside hemodialysis in strict isolation, and eventually fully recovered from COVID-19. CONCLUSIONS: We presented a case of co-infection of influenza and SARS-CoV-2 in a hemodialysis patient. The possibility of SARS-CoV-2 co-infection should not be overlooked even when other viruses including influenza can explain the clinical symptoms, especially in high-risk patients.
背景:2019 年冠状病毒病(COVID-19)是由严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)引起的,这是一种新型冠状病毒,于 2019 年 12 月在中国武汉首次发现。随着全球社区传播病例数量的增加,世界卫生组织(WHO)于 2020 年 3 月 11 日宣布 COVID-19 疫情为大流行。像流感病毒一样,SARS-CoV-2 被认为主要通过飞沫和直接接触传播,COVID-19 的疾病表现与流感相似。在这里,我们报告了一例 60 岁男性透析患者同时感染甲型流感和 COVID-19。
病例介绍:一名 60 岁男性,患有终末期肾病(ESRD),正在接受血液透析,因咳嗽加重、呼吸急促和腹泻就诊。该患者在就诊前 3 天在血液透析过程中首次出现轻度发热(37.8°C),并一直出现类似流感的症状加重,包括高达 38.6°C 的发热、干咳、全身腹痛、恶心、呕吐和绿色稀便。他独自在家居住,没有已知的患病接触者,也否认最近有旅行或除当地透析中心以外的任何医疗机构就诊史。快速流感检测呈甲型流感阳性。降钙素原升高至 5.21ng/mL,白细胞(WBC)计数正常。胸部计算机断层扫描(CT)显示多灶性实变和广泛的纵隔和肺门淋巴结肿大,考虑肺炎。由于可能感染 COVID-19,他被收入内布拉斯加州医学的生物隔离病房,并开始接受奥司他韦治疗流感,万古霉素/头孢吡肟治疗可能导致他肺炎和腹泻的细菌感染。胃肠道(GI)病原体检测和艰难梭菌毒素检测均为阴性。入院第二天,初始鼻咽拭子通过实时逆转录-聚合酶链反应(RT-PCR)检测出 SARS-CoV-2 呈阳性。患者接受了支持性治疗,并在严格隔离下恢复床边血液透析,最终完全从 COVID-19 中康复。
结论:我们报告了一例血液透析患者同时感染流感和 SARS-CoV-2 的病例。即使其他病毒(包括流感)可以解释临床症状,特别是在高危患者中,也不应忽视 SARS-CoV-2 合并感染的可能性。
BMC Infect Dis. 2021-1-13
Medicine (Baltimore). 2020-7-2
Arch Iran Med. 2020-4-1
JMIR Public Health Surveill. 2021-4-28
Beni Suef Univ J Basic Appl Sci. 2021
Ann Intern Med. 2020-6-3
N Engl J Med. 2020-10-8
MMWR Morb Mortal Wkly Rep. 2020-3-27
N Engl J Med. 2020-2-28